Amid a spate of Phase III disasters for Alzheimer's drugs, the FDA is joining the industry chorus and telling drugmakers that they'd be better served by going after early-stage patients who have yet to experience significant brain damage. The high-profile failures of late-stage-targeting drugs such as bapineuzumab and solanezumab are likely to motivate biotechs to shift their focus, and a swell of new programs means a big opportunity for CNS-focused CROs to nab development deals. More